KR101813721B1 - 5-플루오르시토신 제제 및 이의 용도 - Google Patents

5-플루오르시토신 제제 및 이의 용도 Download PDF

Info

Publication number
KR101813721B1
KR101813721B1 KR1020117002457A KR20117002457A KR101813721B1 KR 101813721 B1 KR101813721 B1 KR 101813721B1 KR 1020117002457 A KR1020117002457 A KR 1020117002457A KR 20117002457 A KR20117002457 A KR 20117002457A KR 101813721 B1 KR101813721 B1 KR 101813721B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
oral pharmaceutical
administered
hours
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117002457A
Other languages
English (en)
Korean (ko)
Other versions
KR20110039544A (ko
Inventor
해리 이. 그루버
더글라스 졸리
케이 옴스테드
Original Assignee
토카겐 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 토카겐 인크. filed Critical 토카겐 인크.
Publication of KR20110039544A publication Critical patent/KR20110039544A/ko
Application granted granted Critical
Publication of KR101813721B1 publication Critical patent/KR101813721B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020117002457A 2008-06-30 2009-06-30 5-플루오르시토신 제제 및 이의 용도 Expired - Fee Related KR101813721B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7714208P 2008-06-30 2008-06-30
US61/077,142 2008-06-30
PCT/US2009/049322 WO2010002937A1 (en) 2008-06-30 2009-06-30 Formulations of 5-fluorocytosine and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177036825A Division KR101950635B1 (ko) 2008-06-30 2009-06-30 5-플루오르시토신 제제 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20110039544A KR20110039544A (ko) 2011-04-19
KR101813721B1 true KR101813721B1 (ko) 2017-12-29

Family

ID=41466310

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117002457A Expired - Fee Related KR101813721B1 (ko) 2008-06-30 2009-06-30 5-플루오르시토신 제제 및 이의 용도
KR1020177036825A Expired - Fee Related KR101950635B1 (ko) 2008-06-30 2009-06-30 5-플루오르시토신 제제 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177036825A Expired - Fee Related KR101950635B1 (ko) 2008-06-30 2009-06-30 5-플루오르시토신 제제 및 이의 용도

Country Status (11)

Country Link
US (4) US9320738B2 (https=)
EP (1) EP2306823A4 (https=)
JP (3) JP6092514B2 (https=)
KR (2) KR101813721B1 (https=)
CN (2) CN102076215A (https=)
AU (1) AU2009267052B2 (https=)
BR (1) BRPI0915284B1 (https=)
CA (1) CA2724740C (https=)
IL (3) IL209385A (https=)
MX (2) MX337213B (https=)
WO (1) WO2010002937A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2323744T3 (es) 1998-10-01 2009-07-23 University Of Southern California Sistema retroviral de suministro de genes y metodos de uso.
MX337213B (es) 2008-06-30 2016-02-17 Tocagen Inc Formulaciones de 5-fluorocitosina y usos de las mismas.
CA2738472A1 (en) * 2008-09-26 2010-04-22 Tocagen Inc. Gene therapy vectors and cytosine deaminases
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
DK2443242T3 (en) 2009-06-17 2017-01-30 Tocagen Inc Production cells for replicative retroviral vectors
WO2011057176A1 (en) * 2009-11-06 2011-05-12 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
WO2012058673A2 (en) 2010-10-31 2012-05-03 Tocagen Inc. Enhanced cancer treatment and monitoring using recombinant vectors
WO2012104834A1 (en) * 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
WO2013004658A1 (en) * 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.
CN102579450B (zh) * 2012-02-10 2013-07-24 上海市嘉定区南翔医院 5-氟尿嘧啶在制备局限性慢性湿疹治疗药物上的应用
EP2668945A1 (de) * 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
EP3623478A1 (en) 2012-10-25 2020-03-18 Tocagen Inc. Retroviral vector with mini-promoter cassette
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
AU2016317936A1 (en) 2015-09-04 2018-03-08 Tocagen Inc. Recombinant vectors comprising 2A peptide
CA3056603A1 (en) * 2017-03-14 2018-09-20 Memorial Sloan Kettering Cancer Center Labeling, isolation, & analysis of rna from rare cell populations
US20190380965A1 (en) * 2018-06-15 2019-12-19 Hemant N. Joshi Quick Water-Dispersible Pharmaceutical Compositions of Flucytosine
CA3143952A1 (en) * 2019-02-22 2020-08-27 Candel Therapeutics, Inc. Gmci and ddri combination therapy for treating cancer
WO2021186399A1 (en) 2020-03-18 2021-09-23 Marvell Israel (M.I.S.L) Ltd. Packet buffer spill-over in network devices
CN111937887B (zh) * 2020-07-15 2021-09-07 南京师范大学 5-氟-2’-脱氧尿苷在抑制和/或防治螺旋藻规模化生产中褶皱臂尾轮虫的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069358A1 (ja) * 2005-12-14 2007-06-21 Kissei Pharmaceutical Co., Ltd. 新規胃内滞留製剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ264621A (en) * 1991-03-06 1997-09-22 Wellcome Found Use of 1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluoro-cytosine or a physiologically functional derivative thereof in the preparation of medicaments for treatment of hepatitis b
FI980901A7 (fi) 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
ES2323744T3 (es) 1998-10-01 2009-07-23 University Of Southern California Sistema retroviral de suministro de genes y metodos de uso.
ES2255490T3 (es) * 1999-03-31 2006-07-01 Janssen Pharmaceutica N.V. Almidon pregelatinizado en una formulacion de liberacion controlada.
US6677155B1 (en) 1999-04-22 2004-01-13 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
GB2368846B (en) 1999-07-08 2004-08-25 Univ California Isolated Jaagsiekte retroviruses (JSRV), gene delivery vectors, and methods of use
JP4021627B2 (ja) * 2000-03-22 2007-12-12 株式会社東芝 遺伝子検出用担体、及びインターフェロン療法の有効性を検出するためのその使用
JP2004501190A (ja) 2000-06-23 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
CN1244321C (zh) * 2003-06-26 2006-03-08 李勇 用于胃癌治疗的5－氟尿嘧啶胃内漂浮滞留双层缓释片
US20050049207A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
FR2874325B1 (fr) 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
WO2006127980A2 (en) 2005-05-25 2006-11-30 The Regents Of The University Of California Optimized core promoters and uses therefor
CN101085355B (zh) * 2007-06-20 2012-01-25 山东大学 5-氟胞嘧啶/类水滑石纳米杂化物及其制备方法
US20090068287A1 (en) 2007-09-12 2009-03-12 Susan Welsh Novel topical formulations of flucytosine and uses thereof
US9314524B2 (en) 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
MX337213B (es) * 2008-06-30 2016-02-17 Tocagen Inc Formulaciones de 5-fluorocitosina y usos de las mismas.
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CA2738472A1 (en) 2008-09-26 2010-04-22 Tocagen Inc. Gene therapy vectors and cytosine deaminases
CN103237894A (zh) 2010-08-13 2013-08-07 先锋国际良种公司 包含具有羟基苯丙酮酸双加氧酶(hppd)活性的序列的组合物和方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069358A1 (ja) * 2005-12-14 2007-06-21 Kissei Pharmaceutical Co., Ltd. 新規胃内滞留製剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VERMES, A. et al., ‘Flucytosin:a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions’, Journal of Antimicrobial Chemotherapy, Vol.46, 2000, pp.171-179*

Also Published As

Publication number Publication date
CA2724740A1 (en) 2010-01-07
AU2009267052B2 (en) 2013-07-11
IL209385A0 (en) 2011-01-31
US9889133B2 (en) 2018-02-13
JP6170896B2 (ja) 2017-07-26
MX2010014256A (es) 2011-07-01
US11191764B2 (en) 2021-12-07
JP6092514B2 (ja) 2017-03-08
IL209385A (en) 2016-10-31
EP2306823A1 (en) 2011-04-13
US20160235751A1 (en) 2016-08-18
CA2724740C (en) 2017-02-21
JP2011526918A (ja) 2011-10-20
US20200281929A1 (en) 2020-09-10
CN102076215A (zh) 2011-05-25
BRPI0915284A2 (pt) 2015-08-04
CN107029220A (zh) 2017-08-11
US10449194B2 (en) 2019-10-22
MX337213B (es) 2016-02-17
JP2015063533A (ja) 2015-04-09
EP2306823A4 (en) 2012-09-26
IL255813A (en) 2018-01-31
MX366570B (es) 2019-07-12
WO2010002937A1 (en) 2010-01-07
IL246473B (en) 2018-06-28
US20190015414A1 (en) 2019-01-17
JP2017214398A (ja) 2017-12-07
US20110268720A1 (en) 2011-11-03
US9320738B2 (en) 2016-04-26
AU2009267052A1 (en) 2010-01-07
KR20180004279A (ko) 2018-01-10
BRPI0915284B1 (pt) 2020-01-14
KR20110039544A (ko) 2011-04-19
KR101950635B1 (ko) 2019-05-20

Similar Documents

Publication Publication Date Title
KR101813721B1 (ko) 5-플루오르시토신 제제 및 이의 용도
JP6530772B2 (ja) アンチセンス組成物およびその作製および使用
US20200397726A1 (en) Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms
KR20120046216A (ko) 3-시아노퀴놀린 정제 제형 및 이의 용도
KR20250121109A (ko) Irak4 분해제 및 이의 용도
BRPI0610634A2 (pt) combinação para a terapia de hiperplasia benigna da próstata
EP3718546A1 (en) Controlled-release formulation
US20200101053A1 (en) Method of treating heart failure with preserved ejection fraction by administering milrinone
US20070122481A1 (en) Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20170035768A1 (en) Novel composition for treatment of essential thrombocythemia
HK1239558A1 (en) Formulations of 5-fluorocytosine and uses thereof
AU2013205004B2 (en) Formulations of 5-fluorocytosine and Uses Thereof
HK1154755A (en) Formulations of 5-fluorocytosine and uses thereof
EP2462933A1 (en) Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia
RU2839277C1 (ru) Новая композиция замедленного высвобождения тофацитиниба, его производных и солей
Naidu et al. FORMULATION AND EVALUATION OF MODIFIED RELEASE TABLETS OF GLICLAZIDE
CN120731077A (zh) 膀胱内施用厄达替尼以用于治疗膀胱癌
CN1973820A (zh) 含雷帕霉素的抗癌组合物及其应用
HK1233675A1 (en) Antisense compositions and methods of making and using same

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20201223

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20201223